Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 31Advanced Solid Tumors 25Advanced Solid Tumor 24Carcinoma, Non-Small-Cell Lung 19Neoplasms 15Solid Tumor 12Prostatic Neoplasms 12Multiple Myeloma 11Pancreatic Neoplasms 10Neoplasm Metastasis 10Small Cell Lung Carcinoma 9Recurrence 9Ovarian Neoplasms 9Lung Neoplasms 9Stomach Neoplasms 8Melanoma 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Sarcoma 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Solid Tumors 6Carcinoma, Transitional Cell 5Advanced Solid Tumour 5Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma 4

Interventions

enzalutamide 5Prednisone 5cabazitaxel 4Docetaxel 3Abiraterone Acetate 3fludrocortisone acetate 1Zuclomiphene 1XRP6258 1Standard of Care 1Prednisolone 1Midazolam 1LY3023414 1Injections 1Hydrocortisone 1Dexamethasone 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Prostate Cancer Metastatic × Injections × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡